In April 2023, Avacta Group dosed the first subject in the dose-escalation portion of its Phase I trial of AVA6000 in the US, ...

TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD ...

In the 25 years that I’ve been a beauty writer and editor, I’ve slathered on a slew of anti-aging creams boasting wacky ...

"If we're going to give experimental drugs to try and resolve fibrosis, we have to do it before ... fibroblasts from patients with IPF. By genetically eliminating MKP1 in fibroblasts of mice after ...

Hundreds of FDA-approved drugs tested directly on a patient’s tumor sample. Could this be a gamechanger for cancer management ...

Helping to streamline our beauty tech – and step up the results we can achieve outside of a clinic – is Déesse Pro, whose ...

Financial writer upgrades RCEL stock to Buy due to growth potential, international expansion, and undervaluation ...

Serum analysis revealed that four months of CR treatment in mice (CR serum) activated AMPK in mouse embryonic fibroblasts ... remained stable in mice before and after feeding.

As a result, fibroblasts are activated ... many practitioners recommend annual maintenance treatments. Before you book your treatment, there are a few key things to consider.

However, a month and a half before this news ... which I estimate will be published in late Q4 2024. After 14 weeks of treatment with high-dose duvakitug, 47.8% of patients with ulcerative ...